key: cord-0799811-fpadkdut
authors: Ali, Mohammad Javed
title: Coronavirus Disease 2019 (COVID-19) Pandemic and Lacrimal Practice: Diagnostic and Therapeutic Nasal Endoscopy and Dacryoendoscopy
date: 2020-01-01
journal: Ophthalmic Plast Reconstr Surg
DOI: 10.1097/iop.0000000000001756
sha: 766a39df740e582c6cb41a3be19d77a641af94a1
doc_id: 799811
cord_uid: fpadkdut

nan

To the Editor: Nasal endoscopy is quite a routine pre-and postoperative procedure in well-established lacrimal practices, while dacryoendoscopy has specific indications. 1 The unprecedented crisis of coronavirus disease 2019 (COVID-19) pandemic has forced cancellation of elective endoscopy procedures across the specialties, and lacrimal practice is no exception. 2 While this is important and is currently practiced, prolong deferral can be detrimental with respect to patient morbidity, healthcare, and economic loss. Hence, there is a need for better evidence-based understanding on the safety and optimal utilization of endoscopy for patient care during COVID-19 pandemic.

The nasal tissues have demonstrated shedding of SARS-CoV-2 virus, and nasal interventions are potential aerosol generators. 3, 4 Hence, lacrimal surgeons who perform endoscopy and their staff are at a high risk of virus transmission. This risk can be compounded by the face-to-face position with the patients during examination and the possible sneezing and coughing that can be induced by the procedure. The risk of nasal endoscopy and dacryoendoscopy may be different because the duration of the procedure and its nature (diagnostic or therapeutic) can significantly alter the transmission risk. 5 Dacryoendoscopy usually takes a longer time and therapeutic procedures using it can notably enhance the risks.

The triage of indications for nasal or dacryoendoscopy as emergency, urgency (can be deferred for up to 3-4 weeks with or without conservative management), and elective, even though arbitrary, can be helpful for surgeons to take decisions on operating during this pandemic. Table 1 summarizes these indications, which are by no means an exhaustive list and can itself be a subject of debate. Therefore, individual and institutional discretion based on local government guidelines is advised. Patients who are designated as urgent or elective and their endoscopy examination is deferred should be clearly communicated with and also receive such decisions in writing to avoid medicolegal issues or lawsuits. Table 2 summarizes the precautions to be taken while performing a nasal and a dacryoendoscopy. There are no evidence-based guidelines as to which among the flexible or rigid endoscopy is preferable during COVID-19. 4 The use of topical decongestants and local anesthetics is controversial. If used, the surgeon should preferably avoid spray and instead use soaked pledgets. Care should be taken during this step to avoid reflex sneezing or coughing. It is also important to remember that the virus remains viable on multiple surfaces for hours, 6,7 and the same can be true of endoscopes. Hence, systematic cleaning of all surfaces after endoscopy is crucial for disinfection. There are no special guidelines for sterilization and standard sterilization procedures for endoscopes and instruments are recommended. While performing dacryoendoscopy, it is natural to come in close proximity to the patients while passing the scope through the punctum and canaliculus. Hence, it is advisable to either use an operating microscope or magnifiers or loupes to avoid close contact with the patient's face.

The major question that remains is dealing with emergencies and urgent procedures in suspected COVID-19 patients. All such cases should undergo laboratory testing in the form of polymerase chain reaction test using a nasopharyngeal swab combined with an antibody testing (IgM and IgG). While emergency endoscopy may not be able to wait for the results, the procedure can be performed with full personal protective equipment. The urgent cases can wait for the laboratory results before the procedure. Hence, screening of the patients for COVID-19 symptoms, laboratory tests where needed, adherence to specific operating room guidelines, and personal protective equipment should facilitate performance of nasal endoscopy and dacryoendoscopy during the COVID-19 pandemic.

While the medical communities would continue to experience numerous changes to their endoscopy practice, it would also be an opportunity to consider certain evolving concepts such as the use of imaging in lieu of endoscopy and the utility of disposable endoscopes. 

SARS-CoV-2 viral load in upper respiratory specimens of infected patients

2019-nCoV transmission through the ocular surface must not be ignored

Assessing viral shedding and infectivity of tears in coronavirus disease 2019 (COVID-19) patients

AIOS-OPAI consensus statement on preferred practices in oculoplasty and lacrimal surgery during the COVID-19 pandemic

Povidone-iodine concentration and dosing in cataract surgery

The use of povidone-iodine in ophthalmology

Inactivation of human REFERENCES

A review of diagnostic and therapeutic dacryoendoscopy

German endoscopy unit preparations for the COVID-19 pandemic: a nationwide survey

SARS-CoV-2 viral load in upper respiratory specimens of infected patients

Nasal, pharyngeal and laryngeal endoscopy procedures during COVID-19 pandemic: available recommendations from national and international societies

EUS-guided gallbladder drainage during a pandemic crisis -how the COVID-19 outbreak could impact interventional endoscopy

Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1

Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents

The authors have no financial or conflicts of interest to disclose.

To the Editor: Throughout the coronavirus disease 2019 (COVID-19) pandemic, ophthalmologists have continued to provide medical care to patients with clinically active thyroid eye disease (TED). The first-line treatment of active moderate to severe and sightthreatening TED recommended by the widely accepted guidelines of the European Group on Graves' Orbitopathy (EUGOGO) is high-dose intravenous (IV) methylprednisolone. It also recommends that treatment is delivered in medical facilities, which can safely administer and manage potentially serious adverse events. 1 During this unprecedented COVID-19 crisis, healthcare facilities around the world are required to avoid nonessential medical admissions in order to reduce patient exposure to a hospital/ medical environment and minimize the use of resources needed to combat the viral pandemic. Intravenous methylprednisolone is significantly more efficacious than oral prednisolone as evidenced by a meta-analysis of 29 randomized controlled trials involving corticosteroid treatment of active TED. 2 The decision to administer high-dose methylprednisolone in every patient must be taken on a case-by-case basis, weighing up the potential risks of the treatment against its benefits. However, this decision need not be complicated by logistical concerns over IV administration during a health pandemic, since patients with active moderate or severe TED can be safely managed using oral methylprednisolone